Does the media prefer BCDA or ALGS?

In the previous week, BioCardia had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for BioCardia and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.46 beat BioCardia's score of 0.25 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MDXH or BCDA more profitable?

BioCardia has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets MDxHealth -33.46% N/A -24.25% BioCardia N/A -569.36% -183.15%

Does the media favor MDXH or BCDA?

In the previous week, MDxHealth had 3 more articles in the media than BioCardia. MarketBeat recorded 7 mentions for MDxHealth and 4 mentions for BioCardia. BioCardia's average media sentiment score of 0.25 beat MDxHealth's score of -0.18 indicating that BioCardia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral BioCardia 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IZTC or BCDA?

BioCardia has a consensus price target of $25.00, suggesting a potential upside of 2,258.49%. Given BioCardia's stronger consensus rating and higher possible upside, analysts plainly believe BioCardia is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, IZTC or BCDA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A BioCardia N/A N/A -$8.23M -$0.64 N/A

Is IZTC or BCDA more profitable?

Invizyne Technologies' return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A BioCardia N/A -569.36% -183.15%

Which has higher valuation & earnings, BCDA or RADX?

BioCardia has higher earnings, but lower revenue than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioCardia N/A N/A -$8.23M -$0.64 N/A Radiopharm Theranostics $3.63M 9.71 -$24.83M N/A N/A

Is BCDA or RADX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -569.36% -183.15% Radiopharm Theranostics N/A N/A N/A

Does the media refer more to BCDA or RADX?

In the previous week, BioCardia had 2 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for BioCardia and 2 mentions for Radiopharm Theranostics. BioCardia's average media sentiment score of 0.25 beat Radiopharm Theranostics' score of 0.00 indicating that BioCardia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BioCardia (BCDA) Competitors

$1.06 +0.05 (+4.95%)

Closing price 04:00 PM Eastern

Extended Trading

$1.02 -0.04 (-3.68%)

As of 06:19 PM Eastern

Compare

BCDA vs. ALGS, MDXH, IZTC, RADX, and BTAI

Should you buy BioCardia stock or one of its competitors? BioCardia's main competitors and comparable companies include Aligos Therapeutics (ALGS), MDxHealth (MDXH), Invizyne Technologies (IZTC), Radiopharm Theranostics (RADX), and BioXcel Therapeutics (BTAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioCardia compare to Aligos Therapeutics?

BioCardia (NASDAQ:BCDA) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

BioCardia currently has a consensus price target of $25.00, suggesting a potential upside of 2,258.49%. Aligos Therapeutics has a consensus price target of $38.50, suggesting a potential upside of 455.56%. Given BioCardia's higher probable upside, analysts plainly believe BioCardia is more favorable than Aligos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

BioCardia has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

BioCardia has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Aligos Therapeutics' return on equity of -160.72% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
Aligos Therapeutics	-241.01%	-160.72%	-92.30%

BioCardia has higher earnings, but lower revenue than Aligos Therapeutics. BioCardia is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	N/A	N/A	-$8.23M	-$0.64	N/A
Aligos Therapeutics	$31.52M	1.37	-$24.19M	-$7.30	N/A

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 17.4% of BioCardia shares are owned by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, BioCardia had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for BioCardia and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.46 beat BioCardia's score of 0.25 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aligos Therapeutics beats BioCardia on 10 of the 16 factors compared between the two stocks.

How does BioCardia compare to MDxHealth?

MDxHealth (NASDAQ:MDXH) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

BioCardia has lower revenue, but higher earnings than MDxHealth. BioCardia is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.34	-$33.52M	-$0.72	N/A
BioCardia	N/A	N/A	-$8.23M	-$0.64	N/A

BioCardia has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
BioCardia	N/A	-569.36%	-183.15%

20.6% of BioCardia shares are held by institutional investors. 1.7% of MDxHealth shares are held by company insiders. Comparatively, 17.4% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MDxHealth presently has a consensus target price of $2.17, indicating a potential upside of 192.28%. BioCardia has a consensus target price of $25.00, indicating a potential upside of 2,258.49%. Given BioCardia's higher possible upside, analysts clearly believe BioCardia is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, MDxHealth had 3 more articles in the media than BioCardia. MarketBeat recorded 7 mentions for MDxHealth and 4 mentions for BioCardia. BioCardia's average media sentiment score of 0.25 beat MDxHealth's score of -0.18 indicating that BioCardia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCardia	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MDxHealth has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, BioCardia has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market.

Summary

MDxHealth beats BioCardia on 8 of the 15 factors compared between the two stocks.

How does BioCardia compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

BioCardia has a consensus price target of $25.00, suggesting a potential upside of 2,258.49%. Given BioCardia's stronger consensus rating and higher possible upside, analysts plainly believe BioCardia is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, BioCardia had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for BioCardia and 0 mentions for Invizyne Technologies. BioCardia's average media sentiment score of 0.25 beat Invizyne Technologies' score of 0.00 indicating that BioCardia is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
BioCardia	Neutral

20.6% of BioCardia shares are held by institutional investors. 17.4% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
BioCardia	N/A	N/A	-$8.23M	-$0.64	N/A

Invizyne Technologies' return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
BioCardia	N/A	-569.36%	-183.15%

Summary

BioCardia beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

How does BioCardia compare to Radiopharm Theranostics?

BioCardia (NASDAQ:BCDA) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

BioCardia presently has a consensus price target of $25.00, suggesting a potential upside of 2,258.49%. Radiopharm Theranostics has a consensus price target of $11.00, suggesting a potential upside of 350.82%. Given BioCardia's higher possible upside, equities analysts plainly believe BioCardia is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Radiopharm Theranostics' return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
Radiopharm Theranostics	N/A	N/A	N/A

20.6% of BioCardia shares are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioCardia has higher earnings, but lower revenue than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	N/A	N/A	-$8.23M	-$0.64	N/A
Radiopharm Theranostics	$3.63M	9.71	-$24.83M	N/A	N/A

In the previous week, BioCardia had 2 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for BioCardia and 2 mentions for Radiopharm Theranostics. BioCardia's average media sentiment score of 0.25 beat Radiopharm Theranostics' score of 0.00 indicating that BioCardia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCardia has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market.

Summary

BioCardia and Radiopharm Theranostics tied by winning 6 of the 12 factors compared between the two stocks.

How does BioCardia compare to BioXcel Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 17.4% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioCardia has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%
BioCardia	N/A	-569.36%	-183.15%

BioXcel Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

In the previous week, BioCardia had 4 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 4 mentions for BioCardia and 0 mentions for BioXcel Therapeutics. BioCardia's average media sentiment score of 0.25 beat BioXcel Therapeutics' score of 0.00 indicating that BioCardia is being referred to more favorably in the news media.

Company	Overall Sentiment
BioXcel Therapeutics	Neutral
BioCardia	Neutral

BioXcel Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 1,346.23%. BioCardia has a consensus target price of $25.00, suggesting a potential upside of 2,258.49%. Given BioCardia's higher possible upside, analysts clearly believe BioCardia is more favorable than BioXcel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioCardia has lower revenue, but higher earnings than BioXcel Therapeutics. BioCardia is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$742K	32.09	-$69.90M	-$3.79	N/A
BioCardia	N/A	N/A	-$8.23M	-$0.64	N/A

Summary

BioCardia beats BioXcel Therapeutics on 9 of the 15 factors compared between the two stocks.

Get BioCardia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCDA vs. The Competition

Export

Metric	BioCardia	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.05M	$3.99B	$7.29B	$12.70B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-1.66	11.75	271.38	24.10
Price / Sales	N/A	1,394.70	638.44	90.36
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	13.25	17.26	11.18	6.40
Net Income	-$8.23M	-$22.72M	$3.46B	$348.28M
7 Day Performance	12.77%	2.89%	1.99%	0.91%
1 Month Performance	24.69%	9.74%	7.32%	5.10%
1 Year Performance	-44.50%	54.81%	24.76%	16.16%

BioCardia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCDA BioCardia	3.7618 of 5 stars	$1.06 +5.0%	$25.00 +2,258.5%	-47.1%	$16.05M	N/A	N/A	40	Analyst Forecast
ALGS Aligos Therapeutics	2.7857 of 5 stars	$6.76 +2.9%	$38.50 +469.5%	-34.6%	$43.03M	$2.19M	N/A	90
MDXH MDxHealth	2.1286 of 5 stars	$0.75 -12.2%	$2.83 +277.2%	-77.4%	$39.99M	$107.88M	N/A	300	Analyst Forecast
IZTC Invizyne Technologies	N/A	$6.03 +3.6%	N/A	-23.2%	$37.70M	N/A	N/A	29	Gap Up
RADX Radiopharm Theranostics	2.7775 of 5 stars	$2.62 -1.9%	$11.00 +319.8%	-57.0%	$37.01M	$2.35M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCDA) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCardia (BCDA) Competitors

BCDA vs. ALGS, MDXH, IZTC, RADX, and BTAI

How does BioCardia compare to Aligos Therapeutics?

Summary

How does BioCardia compare to MDxHealth?

Summary

How does BioCardia compare to Invizyne Technologies?

Summary

How does BioCardia compare to Radiopharm Theranostics?

Summary

How does BioCardia compare to BioXcel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCardia (BCDA) Competitors

BCDA vs. ALGS, MDXH, IZTC, RADX, and BTAI

How does BioCardia compare to Aligos Therapeutics?

Do analysts recommend BCDA or ALGS?

Which has more risk & volatility, BCDA or ALGS?

Is BCDA or ALGS more profitable?

Which has preferable earnings and valuation, BCDA or ALGS?

Do insiders & institutionals hold more shares of BCDA or ALGS?

Does the media prefer BCDA or ALGS?

Summary

How does BioCardia compare to MDxHealth?

Which has higher valuation and earnings, MDXH or BCDA?

Is MDXH or BCDA more profitable?

Do insiders & institutionals believe in MDXH or BCDA?

Do analysts recommend MDXH or BCDA?

Does the media favor MDXH or BCDA?

Which has more risk & volatility, MDXH or BCDA?

Summary

How does BioCardia compare to Invizyne Technologies?

Do analysts rate IZTC or BCDA?

Does the media favor IZTC or BCDA?

Do institutionals & insiders hold more shares of IZTC or BCDA?

Which has stronger valuation & earnings, IZTC or BCDA?

Is IZTC or BCDA more profitable?

Summary

How does BioCardia compare to Radiopharm Theranostics?

Do analysts rate BCDA or RADX?

Is BCDA or RADX more profitable?

Do institutionals and insiders have more ownership in BCDA or RADX?

Which has higher valuation & earnings, BCDA or RADX?

Does the media refer more to BCDA or RADX?

Which has more risk and volatility, BCDA or RADX?

Summary

How does BioCardia compare to BioXcel Therapeutics?

Do institutionals and insiders have more ownership in BTAI or BCDA?

Is BTAI or BCDA more profitable?

Which has more risk & volatility, BTAI or BCDA?

Does the media prefer BTAI or BCDA?

Do analysts prefer BTAI or BCDA?

Which has higher valuation and earnings, BTAI or BCDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools